Board of Directors
Karoly Nikolich (Chairman)
Karoly Nikolich is Chairman of the Board of Directors and Chief Executive Officer of Alkahest. During the 1980s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics. He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotech companies, as well as investment funds. Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as postdoctoral fellow at Tulane University and UCSF before joining Genentech. He has been Consulting Professor in the Department of Psychiatry at Stanford University Medical School.
David Bell is Corporate Vice President of Grifols S.A. and General Counsel of Grifols Inc. Mr. Bell is responsible for all legal activities of Grifols’ U.S. Operations. In the U.S., he is also responsible for regulatory, registrations and licensing, compliance, and governmental and public affairs. Mr. Bell serves on the Executive Committee of Grifols, S.A. Prior to joining Grifols in 2003, Mr. Bell was Vice President and General Counsel for Alpha Therapeutic Corporation and a partner in a law firm where he specialized in healthcare, pharmaceutical and biotechnology regulation and liability. Mr. Bell attended the University of California, Southwestern University School of Law and a postgraduate program at Harvard Law School. Mr. Bell also serves as a member of the Global Board of Directors for the Plasma Protein Therapeutics Association.
Mr. Glanzmann has served as a director of Grifols, S.A. since April 2006. He also serves as a Director on the Boards of Sulzer AG, Sage products Inc., and is a Healthcare Advisor to Madison Dearborn and Partners. From 2006 until 2011 he was the Chief Executive Officer and President of Gambro AB. Prior to this, Mr. Glanzmann was the CEO and Managing Director of HemoCue AB. Between 1988 and 2004 he held various positions at Baxter Healthcare: Senior Vice President and Corporate Officer of Baxter Healthcare Corporation; President of Baxter Bioscience; Chief Executive Officer of Immuno International; and President of the European Biotech Group. He also was a Senior Advisor to the Executive Chairman and a Managing Director at The World Economic Forum in Davos from 2004 – 2005 and the Chairman of the Plasma Protein Therapeutics Association (PPTA) between 2000 and 2001. Mr. Glanzmann holds a M.B.A. from IMD in Switzerland, a B.A. in Political Science from Dartmouth College, and a Board of Directors Certification from the UCLA Anderson School of Management.
Joseph S. McCracken
Joe McCracken serves as Alkahest’s Vice President of Business Development. He currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. Joe also serves on the Board of Genkyotex S.A., Savara Pharmaceuticals and Nexvet Biopharma. He was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Joe held the position of Vice President, Business Development at Genentech for more than 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from The Ohio State University.
Tony Wyss-Coray is Professor of Neurology and Neurological Sciences and co-director of the Alzheimer’s Disease Research Center at Stanford University Medical School, and Associate Director of the Center for Tissue Regeneration, Repair and Restoration at the Palo Alto VA. His lab investigates the role of immune responses in brain aging and neurodegeneration with a focus on cognitive decline and Alzheimer’s disease. He combines the study of mouse models with human clinical samples using cytomic, proteomic, and bioinformatics tools. His most recent studies show that systemic circulatory factors can modulate neurogenesis, neuroinflammation, and cognitive function in mice and that factors from young mice can rejuvenate the aging brain. He is the recipient of an NIH Director’s Transformative Research Award, a Zenith award from the Alzheimer’s Association, a distinguished scholar award from the John Douglas French Alzheimer Foundation, and he is an inventor on multiple patents.